Outcome of the Meeting of the Board of Directors of the Company held on November 05, 2026, is attached.

Ref: AHCL/2026-27/C050 November 05, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai – 400 051 Scrip Code – 544350 Symbol : AGARWALEYE Dear Sir / Madam, Sub: Outcome of the Board Meeting held on November 05, 2026 Ref: Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) Pursuant to the captioned subject, reference and in continuation of our letter dated October 23, 2026, we wish to inform that, the Board of Directors of Dr. Agarwal’s Health Care Limited (‘the Company’) at its meeting held today, i.e., Thursday, November 05, 2026, has, inter alia, considered and approved the following: A. Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2026 Pursuant to Regulation 33 of the SEBI Listing Regulations, the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended September 30, 2026, along with the Limited Review Report issued by M/s. S.R. Batliboi & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company and the Press Release are enclosed herewith. Further, the aforesaid Financial Results shall be published in the newspapers in compliance with Regulation 47 of the SEBI Listing Regulations and be made available on the website of the Company at www.dragarwals.co.in. B. Appointment and Re-designation of Dr. Amar Agarwal, Chairman and Non-Executive Director of the Company, as the Executive Chairman (Whole-Time Director) of the Company Consequent to the effectiveness of the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited, Dr. Amar Agarwal, who is presently the Chairman and Non-Executive Director in Dr. Agarwal’s Health Care Limited, has been appointed and re-designated as an Executive Chairman (Whole-Time Director) with Dr. Agarwal’s Health Care Limited and hold office as such, for a period of three years effective November 01, 2026 onwards. The terms and conditions of the aforesaid appointment cum re-designation and the remuneration payable, shall remain identical and exact to those as already drawn by Dr. Amar Agarwal at Dr. Agarwal’s Eye Hospital Limited, which shall be subject to the approval of the members of the Company. The details as required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, regarding the aforesaid appointment cum re-designation are enclosed herewith as Annexure I. C. Postal Ballot Notice for the Appointment and Re-designation of Dr. Amar Agarwal, Chairman and Non-Executive Director of the Company, as the Executive Chairman (Whole-Time Director) of the Company The consent of the members of the Company, for the appointment cum re-designation of Dr. Amar Agarwal, Chairman and Non-Executive Director of the Company, as the Executive Chairman (Whole- Time Director) of the Company, is sought to be obtained via a Postal Ballot process to be convened in accordance with the provisions of Section 110 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 and other applicable laws, rules, circulars & regulations. The Postal Ballot Notice with regard to the aforesaid appointment cum re-designation of Dr. Amar Agarwal was approved by the Board of Directors. The Company shall keep the Stock Exchanges duly informed, regarding the dispatch of the Postal Ballot Notice, Cut-off for e-voting, the e-voting period, and other subsequent stages / developments in due course. The meeting commenced at 04:45 P.M. IST and concluded at 05:53 P.M. IST We request you to kindly take the above on record. For Dr. Agarwal’s Health Care Limited Thanikainathan Arumugam Company Secretary and Compliance Officer Encl.: as above. Press Release November 05, 2026 DR. AGARWAL’S HEALTH CARE LIMITED H1’FY27 Revenue from Operations grows by 28.7% YoY to INR 1,269 Crores H1’FY27 EBITDA grows by 27.0% YoY to INR 362 Crores H1’FY27 PAT grows by 50.1% YoY to INR 112 Crores Chennai, November 05, 2026: Dr. Agarwal’s Health Care Limited (NSE: AGARWALEYE, BSE: 544350), India’s largest eye care service chain(1) operating a network of 305 facilities across India and 19 facilities across Africa, today announced its unaudited consolidated financial results for the half year ended September 30, 2026. Highlights for the Quarter Ended September 30, 2026 (Q2’FY27) - As of September 30, 2026, our network stands at 324 facilities, with 21 new centres added during the quarter comprising 1 tertiary, 17 secondary and 3 primary facilities - Performed 95,841 surgeries during the quarter, growth of 22.2% YoY - Total Income of INR 665 Crores; growth of 31.3% YoY - Revenue from Operations of INR 655 Crores; growth of 31.4% YoY o Revenue from Operations – India of INR 586 Crores, growth of 31.6% YoY - 18.8% Same Store Sales Growth (SSSG) in Q2’FY27 across all facilities set up or acquired up to H1’FY24 - Sale of Services(2) contributed 78.0% and Sale of Products(2) contributed 22.0% to revenue from operations - EBITDA of INR 186 Crores, growth of 28.8% YoY with EBITDA margins of 27.9% - Profit after Tax of INR 57 Crores, growth of 55.8% YoY with PAT margins of 8.5% DR. ACARWAL'S HEALTH CARE LIMITED Registered Office: 6th Floor, Menon Eternity, 1st Main Road, Austin Nagar, Alwarpet, Chennai - 600 018. Tel: +91 44 4378 7777 I CIN: L85100TN2010PLC075403 I GST No: 33AADCD4418MlZO Email: info@dragarwal.comIWebsite:www.dragarwals.co.in Highlights for the Half Year Ended September 30, 2026 (H1’FY27) - As of September 30, 2026, our network stands at 324 facilities, with 39 new centres added during the half year comprising 3 tertiary, 31 secondary and 5 primary facilities - Performed 186,923 surgeries during the half year, growth of 18.8% YoY - Total Income of INR 1,286 Crores; growth of 27.6% YoY - Revenue from Operations of INR 1,269 Crores; growth of 28.7% YoY o Revenue from Operations – India of INR 1,138 Crores, growth of 28.5% YoY - 17.7% Same Store Sales Growth (SSSG) in H1’FY27 across all facilities set up or acquired up to H1’FY24 - Sale of Services(2) contributed 77.9% and Sale of Products(2) contributed 22.1% to revenue from operations - EBITDA of INR 362 Crores, growth of 27.0% YoY with EBITDA margins of 28.2% - Profit after Tax of INR 112 Crores, growth of 50.1% YoY with PAT margins of 8.7% Commenting on the results, Dr. Adil Agarwal, CEO, Dr. Agarwal’s Health Care Limited, said: “The first half of FY27 has been a defining period for us, marked by strong growth across our key metrics. Revenue from Operations grew 28.7% year-on-year to INR 1,269 Crores, and Q2 was our highest-ever quarter at INR 655 Crores. Our mature hospitals continue to lead this growth, with same-store sales growth of 17.7%. EBITDA rose 27.0% to INR 362 Crores despite the investment in new centres, and Profit after Tax grew 50.1% to INR 112 Crores. We added 39 facilities during the half year, taking our network to 324 facilities across India and Africa. In the first half alone, we added more surgical facilities than in all of FY26. We served over 18.4 lakh patients, up 28.5%, and performed c.1.87 lakh surgeries, up 18.8%, supported by a team of 1,100+ doctors. Patients are also increasingly choosing advanced care, with high-end surgeries contributing ~30% of cataract volumes. Beyond these numbers, we continue to push the frontier of eye care. I am pleased to share that we have now opened the world’s first dedicated Pinhole Pupilloplasty (PPP) centre at our Chennai flagship facility. It is a proud milestone for Dr. Agarwal’s and reflects our commitment to clinical innovation. We now intend to take PPP across [Showing first 8,000 characters — download PDF for full document]